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In this study, we aimed to investigate the relationship between body mass index (BMI) and multiple severe 
outcomes of the coronavirus disease 2019 (COVID-19) pneumonia. A total of 1091 patients hospitalized with 
COVID-19 pneumonia were included from Wuhan, China. Overall, 2.8% (n = 31) received invasive mechanical 
ventilation (IMV), 10.8% (n = 118) were admitted to the intensive care unit (ICU), 6.4% (n = 70) developed 
acute respiratory distress syndrome (ARDS), and 4.4% (n = 48) died. Multivariable-adjusted hazard ratios 
(HRs) (95% confidence intervals [CIs]) of IMV therapy, ICU admission and ARDS associated with obesity were 
2.86 (1.16-7.05), 2.62 (1.52-4.49) and 3.15 (1.69-5.88), respectively; underweight was significantly 
associated with death (HR 3.85, 95%CI 1.26-11.76). Restricted cubic spline analyses suggested U-shaped 
associations of BMI with ICU admission and death, but linear relationships of BMI with IMV therapy and 
ARDS. In conclusion, obesity had an increased risk of IMV therapy, ICU admission and ARDS, while 
underweight was associated with higher mortality in COVID-19 pneumonia. U-shaped associations of BMI 
with ICU admission and death, and linear relationships of BMI with IMV therapy and ARDS, were found. 
These findings indicate that extra caution should be taken when treating COVID-19 patients with 
underweight and obesity. 
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INTRODUCTION 
 
The emerging coronavirus disease 2019 (COVID-19) 
first reported in Wuhan, China, is caused by a novel 
beta-coronavirus named severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) [1, 2]. It has 
rapidly spread across international borders causing a 
pandemic [3, 4]. The ongoing COVID-19 pandemic 
poses substantial challenges to global public health. 
 
The clinical spectrum of patients with COVID-19 
ranges from mild to severe illness [5, 6]. Risk factors 
associated with disease severity and outcome have been 
investigated in several studies [7, 8], indicating that 
elderly age was associated with higher risks of acute 
respiratory distress syndrome (ARDS) and death, and 
patients with co-morbidities, such as preexisting 
concurrent cardiovascular or cerebrovascular diseases, 
or ARDS were at an increased risk of death from 
COVID-19 pneumonia [11, 12]. 
 
So far, past studies and meta-analyses note that obesity 
could be a risk factor for severity of COVID-19. In a 
cohort study from US, BMI ≥ 30 kg/m2 was suggested as 
one of the most common comorbidities, accounting for 
41.7% of total study population [3]. Among 4,103 
patients with COVID-19 at an academic medical center 
in New York City, BMI >40 kg/m2 was the second 
strongest significant risk factor for hospitalization 
independently, after old age [9]. Another study from 
France found that the need for invasive mechanical 
ventilation (IMV) was related to a BMI ≥ 35 kg/m2  
[10]. A meta-analysis including 30 studies indicated  
that obesity increased risks for hospitalization, ICU 
admission, IMV requirement and death among 
individuals with COVID-19 [11]. However, the effect of 
underweight on the outcomes of COVID-19 remained 
undetermined. Furthermore, most of those studies were 
conducted in American and European countries. Studies 
among Asian populations were sparse. 
 
Therefore, we aimed to examine the association 
between BMI and multiple severe outcomes of COVID-
19 pneumonia among Chinese patients, including IMV 





A total of 1091 patients hospitalized with COVID-19 
pneumonia were included in this study. The median age 
was 59 years (IQR, 49-67 years), and 509 (46.7%) were 
men. Demographic and biochemical characteristics of the 
included patients are shown in Table 1, stratified by BMI 
categories. Overall, the median BMI was 22.51 kg/m2, 
with the underweight, normal weight, overweight and 
obesity accounting for 7.3%, 45.8%, 20.7% and 26.2% of 
the overall patients, respectively. The levels of neutrophil 
counts, lymphocyte counts, alanine transaminase (ALT), 
serum creatinine and hs-CRP increased with BMI (all p 
values for trend < 0.05). Of the 1091 patients, 430 
(39.4%) patients had comorbidities, including diabetes (n 
= 137 [12.6%]), hypertension (n = 288 [26.4%]), CVD (n 
= 82 [7.5%]), CLD (n = 57 [5.2%]), and cancers (n = 40 
[3.7%]). A total of 690 (63.2%) patients required oxygen 
support in the hospitals. 
 
Of the entire cohort, 2.8% (n = 31) required IMV 
therapy, 10.8% (n = 118) were admitted to the ICU, 
6.4% (n = 70) developed ARDS, and 4.4% (n = 48) 
died. Figure 1 showed the proportions of the clinical 
outcomes from patients with COVID-19 pneumonia by 
BMI category. Patients with obesity had higher rates of 
IMV therapy, ICU admission, ARDS and death, 
compared with the normal weight group. In reverse, the 
proportions of obesity in patients who required IMV 
therapy, who were admitted to ICU, who developed 
ARDS, and who died were higher, ranging from 33.3% 
to 55.7% (Supplementary Figure 2). 
 
The characteristics of patients hospitalized with COVID-
19 pneumonia were summarized in each category of 
clinical outcomes (IMV therapy, ICU admission, ARDS 
status and death) (Table 2). The levels of neutrophil 
counts, ALT, and hs-CRP were higher, while 
lymphocyte counts and platelet counts were lower in 
patients requiring IMV therapy (all p values s < 0.05), 
compared with those without IMV therapy. Patients 
requiring IMV therapy also had a higher proportion of 
comorbidities, including diabetes, CVD and cancers (all 
p values < 0.05). Similar estimates were observed for the 
other three clinical outcomes - ICU admission, ARDS, 
and death. Patients with these clinical outcomes also had 
an elevated rate of IMV therapy. Moreover, patients 
requiring IMV therapy, ICU admission and those with 
ARDS had increased BMI values than their respective 
counterparts (all p values < 0.05). There was no 
statistically significant difference in BMI between the 
death and survival groups. 
 
We further investigated the potential risk factors 
associated with IMV therapy and other clinical 
outcomes of COVID-19 pneumonia (Supplementary 
Table 1). Multivariate Cox regression analyses revealed 
that age ≥ 60 years, men, neutrophil counts, lymphocyte 
counts, platelet counts, hs-CRP and cancer were 
independently associated with IMV therapy, ICU 
admission and ARDS. Several above-mentioned risk 
factors (men, platelet counts and cancer) were not 
associated with death. Each 1 kg/m2 increment of BMI 
was found to be related to IMV therapy and ARDS, but 
not to ICU admission and death. 
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Table 1. Characteristics of patients hospitalized with COVID-19 pneumonia, stratified by BMI categories (n = 1091). 
Characteristics 
Total BMI categories 
(n = 1091) 
Underweight  
(n = 80) 
Normal weight  
(n =500) 
Overweight  
(n = 226) 
Obesity  
(n = 285) 
P for trend 
Men, n (%) 509 (46.7) 15 (18.8) 168 (33.6) 132 (58.4) 194 (68.1) < 0.0001 
Age, years 59.00 (49.00-67.00) 64.00 (48.00-72.00) 59.50 (49.00-67.50) 59.00 (49.00-67.00) 58.00 (49.00-66.50) 0.24 
BMI, kg/m2 22.51 (20.42-25.26) 17.81 (17.17-18.17) 20.76 (19.70-21.90) 24.22 (23.59-24.24) 27.04 (25.95-28.40) < 0.0001 
Hematologic       
  Neutrophils, × 109/L 3.52 (2.61-4.84) 3.33 (2.37-4.37) 3.40 (2.53-4.66) 3.52 (2.76-4.73) 3.72 (2.68-5.25) 0.0001 
  Lymphocytes, × 109/L 1.23 (0.81-1.70) 1.28 (0.83-1.76) 1.28 (0.84-1.70) 1.24 (0.81-1.60) 1.11 (0.73-1.72) 0.02 












Biochemical       
  ALT, U/L 23.50 (15.54-37.40) 15.55 (10.80-23.13) 21.83 (14.35-35.60) 25.73 (17.39-40.96) 28.77 (18.20-44.10) < 0.0001 
  Serum creatinine, umol/L 63.60 (53.00-76.00) 56.60 (50.85-63.80) 60.00 (52.20-72.20) 65.60 (53.10-77.90) 70.10 (59.90-81.60) < 0.0001 
hs-CRP, mg/L 7.58 (1.43-49.04) 4.21 (0.79-19.06) 4.97 (1.18-32.92) 16.99 (1.86-61.42) 20.14 (2.18-75.76) < 0.0001 
Comorbidities       
  Diabetes, n (%) 137 (12.6) 7 (8.8) 62 (12.4) 33 (14.7) 35 (12.4) 0.53 
  Hypertension, n (%) 288 (26.4) 18 (22.5) 119 (23.8) 65 (28.8) 86 (30.2) 0.16 
  CVD, n (%) 82 (7.5) 2 (2.5) 40 (8.0) 14 (6.2) 26 (9.1) 0.22 
  CLD, n (%) 57 (5.2) 4 (5.0) 29 (5.8) 9 (4.0) 15 (5.3) 0.73 
  Cancer, n (%) 40 (3.7) 4 (5.0) 18 (3.6) 8 (3.5) 10 (3.5) 0.70 
Oxygen therapy       
  Nasal cannula, n (%) 607 (57.3) 55 (69.6) 283 (58.8) 122 (55.2) 147 (52.7) 0.009 
  NPPV, n (%) 176 (16.2) 11 (13.8) 55 (11.0) 43 (19.0) 67 (23.5) < 0.0001 
  HFNC, n (%) 87 (8.0) 5 (6.3) 29 (5.8) 20 (8.9) 33 (11.6) 0.005 
  IMV, n (%) 31 (2.8) 0 10 (2.0) 4 (1.8) 17 (6.0) 0.0007 
Data are n (%) or median (IQR). ALT, alanine transaminase. ARDS, acute respiratory distress syndrome. BMI, body mass index. 
CLD, chronic lung disease. COVID-19, coronavirus disease 2019. CVD, cardiovascular disease. HFNC, high flow nasal cannula. 





Figure 1. Proportions of COVID-19 pneumonia patients with the outcomes according to BMI categories. ARDS, acute respiratory 
distress syndrome. BMI, body mass index. COVID-19, coronavirus disease 2019. IMV, invasive mechanical ventilation. ICU, intensive care unit. 
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Table 2. Characteristics of patients hospitalized with COVID-19 pneumonia, stratified by the outcome. 
Characteristics 
IMV therapy  ICU admission   ARDS  Death 
Not receiving 
IMV therapy  
(n = 1060) 
Receiving IMV 




(n = 973) 
ICU admission  
(n = 118) 
 
Without ARDS  
(n = 1021) 
With ARDS  
(n = 70) 
 
Alive  
(n = 1043) 
Died  
(n = 48) 









































Hematologic            





 3.42 (2.57-4.51) 5.43 (3.33-7.88) *  3.46 (2.60-4.61) 5.51 (3.00-8.29) *  3.46 (2.58-4.65) 5.51 (4.68-9.68) * 
  Lymphocytes, × 
109/L 
1.25 (0.82-1.71) 0.68 (0.45-0.83) *  1.31 (0.89-1.74) 0.66 (0.46-0.84) *  1.28 (0.86-1.72) 0.64 (0.45-0.79) *  1.26 (0.83-1.71) 0.65 (0.45-0.87) * 
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Comorbidities            
  Diabetes, n (%) 128 (12.1) 8 (25.8) *  111 (11.4) 26 (22.0) *  123 (12.1)  14 (20.0)   124 (11.9) 13 (27.1) * 
  Hypertension, n 
(%) 
277 (26.1) 10 (32.3)  243 (25.0) 45 (38.1) *  264 (25.9) 24 (34.3)  271 (26.0) 17 (35.4) 
  CVD, n (%) 75 (7.1) 6 (19.4) *  62 (6.4) 20 (17.0) *  70 (6.9) 12 (17.1) *  75 (7.2) 7 (14.6) 
  CLD, n (%) 55 (5.2) 2 (6.5)  50 (5.1) 7 (5.9)  54 (5.3) 3 (4.3)  53 (5.1) 4 (8.3) 
  Cancer, n (%) 36 (3.4) 4 (12.9) *  27 (2.8) 13 (11.0) *  32 (3.1) 8 (11.4) *  36 (3.5) 4 (8.3) 
Oxygen therapy            
  Nasal cannula, 
n (%) 
597 (56.3) 7 (31.8) *  572 (58.9) 35 (39.8) *  601 (59.5) 6 (12.2) *  589 (57.4) 18 (54.6) * 
  NPPV, n (%) 167 (15.8) 9 (29.0) *  106 (10.9) 70 (59.3) *  138 (13.5) 38 (54.3) *  152 (14.6) 24 (50.0) * 
  HFNC, n (%) 77 (7.3) 10 (32.3) *  48 (4.9) 39 (33.1) *  62 (6.1) 25 (35.7) *  76 (7.3) 11 (22.9) * 
  IMV, n (%) 0 31  1 (0.1) 30 (25.4) *  6 (0.6) 6 (12.2) *  12 (1.2)) 19 (39.6) * 
Data are n (%) or median (IQR). ALT, alanine transaminase. ARDS, acute respiratory distress syndrome. BMI, body mass index. 
CLD, chronic lung disease. COVID-19, coronavirus disease 2019. CVD, cardiovascular disease. HFNC, high flow nasal cannula. 
hs-CRP, high-sensitivity C-reactive protein. IMV, invasive mechanical ventilation. NPPV, non-invasive positive pressure 
ventilation. * P < 0.05 
The risk of requiring IMV therapy and other clinical 
outcomes of COVID-19 pneumonia according to BMI 
categories was further analyzed. As demonstrated in 
Table 3, compared with patients in the normal weight 
group, those obese had an increased risk of requiring 
IMV therapy (HR 2.86, 95% CI 1.16-7.05), ICU 
admission (HR 2.62, 95% CI 1.52-4.49) and 
developing ARDS (HR 3.15; 95% CI 1.69-5.88) in the 
multivariable-adjusted model. However, the 
association of obesity and with death was not 
significant in the adjusted model. However, 
underweight was associated with a 2.85-fold higher 
risk of death after adjusting for potential confounders 
(HR 3.85, 95% CI 1.26-11.76). The test for interaction 
of age, hypertension and cancer, with obesity on the 
risk of IMV therapy, ICU admission and ARDS, was 
statistically significant (not for other stratified 
variables or death, all p-values for interaction < 0.05, 
data not shown). When we further adjusted diabetes 
(yes/no), hypertension (yes/no), CVD (yes/no), and 
center, the results did not change appreciably 
(Supplementary Table 2). Multivariable-adjusted 
restricted cubic spline analyses suggested “U-shaped” 
associations between BMI and both ICU admission 
and death of COVID-19 pneumonia, which indicated 
significant nonlinear relationships (both P < 0.0001) 
(Figure 2). There was evidence of a significant linear 
relationship of BMI with IMV therapy and ARDS 




In this cohort study, we investigated the associations of 
BMI with multiple severe outcomes in patients with 
COVID-19 pneumonia, including IMV therapy, ICU 
admission, development of ARDS, and death. We found 
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Table 3. The association between BMI category and outcome in patients with COVID-19 pneumonia. 
 BMI subgroups 
Underweight Normal weight  Overweight  Obesity  
IMV therapy     
  Model 1 NA 1.00 0.88 (0.27-2.83) 3.11 (1.40-6.88) 
  Model 2 NA 1.00 0.85 (0.24-2.98) 2.86 (1.16-7.05) 
ICU admission     
  Model 1 1.94 (0.95-3.97) 1.00 0.93 (0.51-1.70) 2.78 (1.78-4.34) 
  Model 2 2.18 (0.94-5.08) 1.00 0.84 (0.42-1.68) 2.62 (1.52-4.49) 
ARDS     
  Model 1 0.28 (0.04-2.07) 1.00 0.80 (0.35-1.82) 3.44 (2.00-5.94) 
  Model 2 0.23 (0.03-1.85) 1.00 0.71 (0.29-1.73) 3.15 (1.69-5.88) 
Death     
  Model 1 3.71 (1.27-10.79) 1.00 0.57 (0.15-2.10) 2.50 (1.08-5.79) 
  Model 2 3.85 (1.26-11.76) 1.00 0.53 (0.14-2.00) 1.75 (0.73-4.21) 
Model 1: unadjusted. 
Model 2: adjusted for age, sex, neutrophil counts, lymphocyte counts, platelet counts, hs-CRP, and cancer (yes/no). 
ARDS, acute respiratory distress syndrome. BMI, body mass index. HR, hazard ratio. ICU, intensive care unit. IMV, invasive 




Figure 2. Multivariable-adjusted HRs (95% CIs) for the associations of IMV therapy (A), ICU admission (B), ARDS (C) and death (D) with BMI. 
HRs (95% CIs) were adjusted for age, sex, neutrophil counts, lymphocyte counts, platelet counts, hs-CRP, and cancer (yes/no). ARDS, acute 
respiratory distress syndrome. BMI, body mass index. ICU, intensive care unit. IMV, invasive mechanical ventilation. Red line, HR; dotted grey 
lines, 95% CI. 
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that patients with obesity had an increased risk of IMV 
therapy, ICU admission and developing ARDS. In 
addition, underweight was independently associated 
with death. Our data further suggested U-shaped 
associations of BMI with ICU admission and death. 
However, a linear relationship was detected for BMI 
with IMV therapy and ARDS. These findings suggest 
that patients with obesity or underweight were at higher 
risks of severe outcomes from COVID-19 pneumonia 
and thus extra caution should be taken when treating 
COVID-19 patients with underweight and obesity. 
 
The COVID-19 pandemic has led to the global research 
efforts to identify individuals at the greatest risk of 
developing critical illness, including death. Previous 
studies have shown that older individuals are particularly 
vulnerable, as well as those with metabolic 
comorbidities [8, 12]. Evidence has recently emerged 
regarding the association between a higher prevalence of 
obesity among COVID-19 patients and an increased risk 
of poor prognosis from SARS-CoV-2 infection. A 
descriptive study with 24 critically ill patients diagnosed 
with COVID-19 in the Seattle region was among the 
first to report BMI data [13], showing that 85.0% of the 
patients with obesity required mechanical ventilation and 
62.0% of the patients with obesity died. These 
proportions were greater than those in the patients 
without obesity. In a latest cohort study from the US 
with more than 5700 patients [9], obesity (BMI ≥ 30 
kg/m2) was suggested as one of the most common 
comorbidities, accounting for 41.7% of the total study 
population. In our study, we found that among patients 
who required IMV therapy, were admitted to ICU, 
developed ARDS, and those who died, the prevalence 
rates of obesity were 61.9%, 52.6%, 64.4% and 46.4%, 
respectively (data not shown). We also reported higher 
proportions of receiving IMV therapy, requirement of 
ICU admission, development of ARDS and death in 
obese patients than those with normal weight 
(unadjusted), which was consistent with the published 
data. 
 
In a small study consisting of 124 patients with 
COVID-19 from France [10], the need for IMV therapy 
was found to be associated with a BMI ≥ 35 kg/m2, 
independently from other comorbidities. Data from 
Shenzhen, China with 383 COVID-19 patients revealed 
that overweight was associated with an 86% higher, and 
obesity with a 142% higher, risk of developing severe 
pneumonia compared with patients with normal weight 
[14]. A recent study with 214 patients from Wenzhou 
[15], China reported a 6-fold increased risk of severe 
COVID-19 illness, but with a large 95% confidence 
intervals. Our study showed an increased risk of IMV 
therapy, ICU admission and developing ARDS 
(adjusted) among obese patients, using the World 
Health Organization recommendations for Asian 
populations as BMI ≥ 25 kg/m2 to define obesity. 
 
Multiple studies have observed the associations between 
obesity and death with COVID-19, which was not 
found significant in our study after adjusting for other 
variables. One possible reason could be that the 
prevalence of obesity, especially severe obesity in 
Chinese population is extremely lower than that in 
western countries. As evidenced in recent data, the 
prevalence of obesity is 6.2% in China, versus 40% in 
the USA, 20% in Italy, and 24% in Spain [16]. Besides, 
many studies demonstrated that the excess risk from 
obesity on death was limited mostly to the younger 
patients with class III obesity (BMI ≥ 40 kg/m2). Tartof 
et al reported that a higher BMI (≥ 40 kg/m2) was 
associated with an increased risk of death from COVID-
19 [17], particularly in male patients and younger 
individuals (≤60 years), in both outpatients and 
inpatients. S. Hendren et al found that the association of 
BMI with death or mechanical ventilation was strongest 
in adults ≤50 years [18]; severe obese individuals (BMI 
≥40 kg/m2) had an increased risk of in-hospital death, 
only in those ≤50 years (hazard ratio, 1.36 [1.01–1.84]). 
However, the number of patients with BMI ≥ 40 kg/m2 
was sparse in our study, which might explain why the 
adjusted effect of obesity on death was not identified in 
the current study. 
 
From an indirect perspective, obesity and excess fat 
mass are commonly related to other comorbidities, such 
as hypertension, diabetes, CVD and renal disease, which 
are considered to result in increased vulnerability to 
pneumonia-associated organ failures [19]. For example, 
in individuals with diabetes, obesity and excess ectopic 
fat lead to impairment of beta-cell function and 
increased insulin resistance. Therefore, an appropriate 
metabolic response upon immunologic challenge was 
limited, resulting in some diabetes patients requiring 
substantial amounts of insulin during severe infections 
[20]. Patients with obesity often have respiratory 
dysfunction, which is characterized by alterations in 
respiratory mechanisms, increased airway resistance, 
impaired gas exchange, diminishing forced volume and 
forced vital capacity, possibly leading to ARDS. With 
respect to the immune response, there is a clear 
association between obesity and basal inflammatory 
status characterized by higher circulating Interleukin 6 
and CRP levels. Actually, adipose tissue in obesity is 
“pro-inflammatory”, with increased expression of 
cytokines and particularly adipokines. Obesity was 
reported to impair adaptive immune responses to 
influenza virus [21], and conceivably could do so in 
COVID-19. Our study showed higher levels of hs-CRP 
in obese patients than those with normal weight, 
indicating strong systemic inflammation. 
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In this study, underweight was significantly associated 
with an increased risk of death, and a U-shaped 
association between BMI and death was identified. That 
is, both underweight and obesity showed increased trend 
and risk of death due to COVID-19, compared with  
the normal weight. In a retrospective cohort study with 
1687 hospitalized patients, being underweight had a 
statistically significant association with an increased risk 
for death (HR=2.37, 95%CI 1.50–3.75) [22], which was 
consistent with our findings. In another study with 10,861 
patients with COVID-19 infection, being underweight 
was suggested to have a non-significant association  
with IMV, but have a higher risk of death (OR = 1.44, 
95% CI 1.08-1.92) [23]. It can be speculated that being 
underweight is often associated with malnutrition, 
impaired immune function, underlying frailty along with 
coexisting chronic conditions. Furthermore, being 
underweight is at an increased risk for pneumonia, and 
worse outcomes among older hospitalized patients [24]. 
 
To the best of our knowledge, this was the one of the 
limited studies among Asian population to investigate the 
association of BMI and multiple severe outcomes of 
COVID-19 pneumonia. Our present study was subjected 
to some limitations. First, the number of cases of IMV 
therapy outcome in the underweight group was too small 
to perform the analysis, which could reduce the robust of 
the analysis result. Second, although most height and 
weight values were retrieved from medical chart records, 
some were self-reported, which may lead to measurement 
bias. Third, even though potential influencing factors had 
been adjusted, our results might still be confounded by 
other factors that are unavailable in current study, such as 
lifestyle information and therapeutic agents use. Fourth, 
the definition of obesity (BMI ≥25 kg/m2) in this study 
was appropriate for Asians, so comparability of the 
findings with other studies which have used the BMI cut-
off of 30 kg/m2 is compromised. 
 
In conclusion, our study suggested that patients with 
underweight or obesity experienced more severe 
outcomes than those of normal weight when being 
hospitalized with COVID-19 pneumonia. Our findings 
highlight the significant role of BMI in clinical 
progression of COVID-19 pneumonia, and this should 
be kept in mind when treating COVID-19 patients with 
underweight and obesity. 
 




This two-center, retrospective cohort study was 
conducted at the Sixth Hospital of Wuhan and Taikang 
Tongji Hospital of Wuhan, which were the two 
government-designated hospitals for the patients with 
COVID-19. The cohort consisted of 1171 adult patients 
aged 21 to 93 years old with confirmed COVID-19 
pneumonia who were admitted between January 1 to 
March 1, 2020 and who died or were discharged before 
March 30, 2020. COVID-19 pneumonia was diagnosed 
according to World Health Organization (WHO) interim 
guidance [25]. In our study, we excluded patients with 
missing data of BMI (n = 58). We further excluded 22 
patients who didn’t have data on the outcomes (IMV 
therapy, ICU admission, development of ARDS, or 
death), resulting in 1091 patients for this analysis 
(Supplementary Figure 1). The ethics committee of the 
Sixth Hospital of Wuhan and Shanghai East Hospital 
approved this study and empowered a waiver of informed 




Patients’ demographic characteristics data, such as age 
and sex, were extracted from the electronic medical 
records. The data on the underlying comorbidities were 
extracted from patients’ reports of past medical history, 
including diagnosed type 2 diabetes mellitus (T2DM), 
hypertension, cardiovascular disease (CVD), chronic 
lung disease (CLD), and cancer. Blood tests on 
admission were extracted from the electronic medical 
records including hematologic and biochemical indexes. 
A standardized data collection form was used by a team 
of experienced respiratory clinicians. Data were double 
checked by a third reviewer if there was a disagreement. 
Anthropometric measurements, including body weight 
and height were performed by trained nurses according 
to standard protocols. BMI (kg/m2) was calculated by 
dividing weight (kg) by height (m) squared. The 
majority of the BMI data (n = 1048) used in this study 
were calculated based on the measurements on the first 
day of hospital admission, and the rest of BMI data (n = 
43) were calculated according to self-reported height 
and weight values obtained from the patients and their 
family members. 
 
For the diagnosis of SARS-CoV-2 infection, plasma and 
nasopharyngeal swab samples were obtained from all 
patients upon hospital admission and tested for targeted 
NP gene segment by real-time reverse transcription 
polymerase chain reaction (RT-PCR) assays as described 
elsewhere [1]. The requirement of oxygen therapy during 
hospitalization (nasal cannula, noninvasive positive 
pressure ventilation [NPPV], high flow nasal cannula 
oxygen therapy (HFNC), or invasive mechanical 
ventilation [IMV]) was recorded during hospitalisation. 
 
Assessment of obesity 
 
BMI was categorized by the definitions as follows: 1) 
underweight (BMI < 18.5kg/m2); 2) normal weight 
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(BMI 18.5–23 kg/m2); 3) overweight (BMI 23– 25 
kg/m2); 4) obesity (BMI ≥ 25 kg/m2) according to the 
World Health Organization recommendations for Asian 
populations [26]. The validity of this definition has been 
confirmed previously [27, 28]. 
 
Follow-up and outcome assessment 
 
The information on clinical outcomes was obtained 
from the electronic medical records and verified by two 
authors (C.H.L and X.D.W). The investigated outcomes 
included requirement of IMV therapy, ICU admission, 
development of ARDS, and death. The definition of 
ARDS was according to the interim guidance of WHO 
for SARS-CoV-2 [25]. Briefly, the definition criteria for 
ARDS were as follows: acute onset within 1 week of 
new or worsening respiratory symptoms; the radio-
graphic images showing bilateral opacities not fully 
explained by lobar or lung collapse, effusions, or 
nodules; the oxygenation was impaired as measured by 
a PaO2/FiO2 (fraction of inspired oxygen) not exceeding 
300 mmHg with a minimal positive end-expiratory 




Demographic and biochemical characteristics from the 
included patients were summarized as medians 
(interquartile ranges [IQRs]) for the continuous variables 
and numbers (proportions) for the categorical variables, 
stratified by BMI category, and by clinical outcome (IMV 
therapy, ICU admission, ARDS and death) respectively. 
The differences across the BMI categories or the clinical 
outcomes were determined by one-way ANOVA (for 
continuous variables) or the χ2 test (the categorical 
variables). We tested the p values for trend through the 
BMI categories treating BMI as an ordinal variable. 
 
In order to analyze the associations of BMI with clinical 
outcomes (IMV therapy, ICU admission, ARDS and 
death), univariable and multivariable Cox proportional 
hazards models were performed. Proportional hazards 
assumption was verified by regressing Schoenfeld 
residuals over time. Hazard ratios (HRs) and the 
corresponding 95% confidence intervals (CIs) for 
potential risk factors and each BMI subgroup in relation 
to these events were further evaluated, using the normal 
BMI (BMI 18.5–23kg/m2) as a reference. In the time-to-
event analysis, data were censored at the time of death 
or the discharge-whichever occurred first. Covariates in 
the multivariate-adjusted models include age, sex, 
neutrophil counts, lymphocyte counts, platelet counts, 
high-sensitivity C-reactive protein (hs-CRP), and cancer 
(yes/no). The p values for interaction were calculated by 
a likelihood ratio test comparing models with and 
without the interaction terms. 
We examined the potential non-linear associations 
between the level of BMI and the incidence of IMV 
therapy and other clinical outcome using restricted 
cubic splines. Analyses were multivariate-adjusted, 
using three knots, which were located at the 5th, 50th 
and 95th percentiles for baseline BMI levels, and the 
highest and lowest 0.5% were trimmed. Tests for non-
linearity, which compared a model containing only the 
linear term with a model containing the linear and 
restricted cubic spline terms, were performed using 
likelihood ratio tests. If a test for non-linearity was not 
significant, a test for linearity was performed, 
comparing a model containing the linear term with a 
model containing only the covariates of interest. 
 
PASS 15 software was used to test the statistical power. 
The effect size we anticipated was at least 1.49 based on 
the previous studies [11]. It is suggested that we had a 
99% chance of detecting a 49% increased risk of IMV 
therapy, ICU admission, development of ARDS, and 
death in patients with obesity at an alpha level of 0.05 in 
the present study. Significance tests were two-tailed, 
with a p value < 0.05 considered as statistically 
significant. Statistical analysis was performed using 
SAS version 9.4 (SAS Institute, Cary, NC, USA). 
 
Data availability statement 
 
All data used during the study are available from the 




ALT: alanine transaminase; AST: aspartate transaminase; 
ARDS: acute respiratory distress syndrome; BMI: body 
mass index; CI: confidence interval; CLD: chronic lung 
disease; COVID-19: coronavirus disease 2019; CVD: 
cardiovascular disease; HFNC: high-flow nasal cannula 
oxygen therapy; HR: hazard ratio; hs-CRP: high-
sensitivity C-reactive protein; ICU: intensive care unit; 
IMV: invasive mechanical ventilation; IQR: Inter 
Quartile Range; NA: not available; NPPV: noninvasive 
positive-pressure ventilation; NPS: nasopharyngeal swab; 
RT-PCR: reverse transcription polymerase chain 
reaction; SARS-CoV-2: severe acute respiratory 
syndrome coronavirus 2; T2DM: type 2 diabetes 
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Supplementary Figure 1. Flowchart of study population. BMI, body mass index. 
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Supplementary Figure 2. Proportions of BMI categories according to the outcomes of COVID-19 pneumonia. ARDS, acute 
respiratory distress syndrome. BMI, body mass index. COVID-19, coronavirus disease 2019. IMV, invasive mechanical ventilation. ICU, 
intensive care unit. 
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Supplementary Tables 
 
Supplementary Table 1. Univariable and multivariable Cox regression of risk factors associated with outcome in 
patients with COVID-19 pneumonia. 
 IMV therapy  ICU admission  ARDS  Death 
 Model 1 Model 2  Model 1 Model 2  Model 1 Model 2  Model 1 Model 2 
Sex (male vs 
female) 
2.87 (1.31-6.29) 2.93 (1.33-6.45)  2.08 (1.40-3.08) 2.15 (1.44-3.20)  2.65 (1.58-4.46) 2.71 (1.61-4.57)  1.52 (0.76-3.06) 1.51 (0.75-3.04) 
Age (≥60 vs < 60), 
years 
3.60 (1.54-8.43) 3.67 (1.57-8.62)  3.05 (1.99-4.66) 3.12 (2.03-4.78)  2.69 (1.58-4.58) 2.75 (1.61-4.70)  3.34 (1.37-8.15) 3.33 (1.36-8.12) 
BMI, kg/m2 1.17 (1.07-1.28) 1.19 (1.07-1.31)  1.11 (1.05-1.17) 1.05 (0.97-1.11)  1.21 (1.13-1.29) 1.21 (1.13-1.30)  1.00 (0.91-1.10) 1.01 (0.91-1.12) 
Hematologic            
Neutrophils, × 
109/L 
1.16 (1.07-1.25) 1.14 (1.06-1.22)  1.26 (1.19-1.34) 1.24 (1.17-1.33)  1.18 (1.11-1.26) 1.16 (1.09-1.24)  1.12 (1.08-1.16) 1.13 (1.09-1.17) 
Lymphocytes, × 
109/L 

















 1.00 (0.99-1.01) 0.99 (0.98-1.00) 
Biochemical            
ALT, U/L 1.00 (1.00-1.02) 1.00 (0.99-1.02)  1.01 (1.00-1.02) 0.99 (0.97-1.01)  
1.008 (1.001-
1.015) 






1.00 (0.99-1.01)  1.01 (1.00-1.02) 1.00 (0.99-1.03)  1.00 (0.99-1.01) 1.00 (0.99-1.01)  1.01 (1.00-1.02) 1.00 (0.99-1.02) 
hs-CRP, each 10 
increment, mg/L 
1.19 (1.13-1.26) 1.17 (1.11-1.24)  1.21 (1.16-1.25) 1.18 (1.14-1.23)  1.12 (1.06-1.18) 1.17 (1.12-1.22)  1.20 (1.13-1.27) 1.18 (1.12-1.25) 
Comorbidities            
Diabetes (yes vs 
no) 
2.51 (1.10-5.74) 1.92 (0.83-4.46)  2.19 (1.36-3.53) 1.73 (1.06-2.84)  1.82 (0.98-3.37) 1.43 (0.76-2.69)  2.14 (0.96-4.77) 1.83 (0.81-4.11) 
Hypertension 
(yes vs no) 
1.34 (0.62-2.88) 0.96 (0.44-2.10)  1.85 (1.24-2.76) 1.41 (0.93-2.13)  1.50 (0.90-2.50) 1.16 (0.42-1.72)  1.67 (0.80-3.49) 1.25 (0.59-2.65) 
CVD (yes vs 
no) 
3.14 (1.25-7.89) 2.12 (0.82-5.50)  3.00 (1.74-5.18) 2.11 (1.20-3.77)  2.81 (1.44-5.48) 2.03 (1.01-4.07)  1.72 (0.60-4.92) 1.29 (0.45-3.71) 
CLD (yes vs no) 1.26 (0.29-5.40) 0.83 (0.19-3.65)  1.16 (0.52-2.63) 0.82 (0.36-1.89)  0.80 (0.24-2.63) 0.55 (0.17-1.85)  1.94 (0.59-6.39) 1.54 (0.46-5.12) 






 4.34 (2.17-8.66) 3.94 (1.90-8.15)  3.99 (1.76-9.02) 3.64 (1.55-8.54)  2.50 (0.84-7.46) 2.11 (0.71-6.29) 
Model 1: unadjusted. 
Model 2: adjusted for age and sex. 
ALT, alanine transaminase. ARDS, acute respiratory distress syndrome. CLD, chronic lung disease. BMI, body mass index. CLD, 
chronic lung disease. CVD, cardiovascular disease. HR, hazard ratio. hs-CRP, high-sensitivity C-reactive protein. ICU, intensive 
care unit. IMV, invasive mechanical ventilation. OR, odds ratio. 
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Supplementary Table 2. The association between BMI category and outcome in patients with COVID-19 pneumonia. 
 BMI subgroups 
 Underweight Normal weight  Overweight  Obesity  
IMV therapy     
  Model 1 NA 1.00 0.88 (0.27-2.83) 3.11 (1.40-6.88) 
  Model 2  NA 1.00 0.85 (0.24-2.98) 2.85 (1.15-7.05) 
ICU admission     
  Model 1 1.94 (0.95-3.97) 1.00 0.93 (0.51-1.70) 2.78 (1.78-4.34) 
  Model 2  2.17 (0.94-5.05) 1.00 0.84 (0.42-1.68) 2.62 (1.52-4.49) 
ARDS     
  Model 1 0.28 (0.04-2.07) 1.00 0.80 (0.35-1.82) 3.44 (2.00-5.94) 
  Model 2  0.23 (0.03-1.85) 1.00 0.70 (0.29-1.73) 3.16 (1.69-5.88) 
Death     
  Model 1 3.71 (1.27-10.79) 1.00 0.57 (0.15-2.10) 2.50 (1.08-5.79) 
  Model 2  3.83 (1.22-11.71) 1.00 0.53 (0.14-2.00) 1.74 (0.73-4.21) 
Model 1: unadjusted.  
Model 2: adjusted for age, sex, neutrophil counts, lymphocyte counts, platelet counts, hs-CRP, cancer (yes/no), diabetes 
(yes/no), hypertension (yes/no), CVD (yes/no), and center.  
We did a sensitivity analysis to investigate the associations of BMI with IMV therapy, ICU admission, development of ARDS, 
and death with additional adjustment for center, diabetes, hypertension and CVD. The HRs for all subgroups were generally 
comparable with the main analysis.  
ARDS, acute respiratory distress syndrome. BMI, body mass index. CVD, cardiovascular disease. ICU, intensive care unit. IMV, 
invasive mechanical ventilation. 
